Search
Etretinate
go.drugbank.com/drugs/DB00926ApprovedWithdrawnEtretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas.
Lanthanum carbonate
go.drugbank.com/drugs/DB06792ApprovedIt is used to treat elevated phosphate levels, primarily in patients with chronic kidney disease, by binding to dietary phosphate and preventing its absorption in the intestine.[L50733]
Diroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigationalDiroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225] … [A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe.
Alprenolol
go.drugbank.com/drugs/DB00866ApprovedWithdrawnAlprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties. … One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnMarginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. … [A229668] On February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib, a kinase inhibitor for PI3K-delta and casein kinase CK1-epsilon, based on promising results
Oxymetholone
go.drugbank.com/drugs/DB06412ApprovedIllicitin malnourished or underdeveloped patients. … Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth
Isocarboxazid
go.drugbank.com/drugs/DB01247Approved[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. … [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.
Enoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalEnoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. … Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.
Products: LOVENOX 10.000 IE (100 mg)/1 ml Injektionslösung in einer Fertigspritze, LOVENOX 15.000 IE (150 mg)/1 ml Injektionslösung in einer FertigspritzeZileuton
go.drugbank.com/drugs/DB00744ApprovedWithdrawnBoth the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market. … These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients.
Synonyms: N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea, N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyureaLumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnNew Zealand and Canada have also followed suit in recalling the drug. … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver